Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 25SFRNPCKMS1463898 | Other Grant/Funding Number | American Heart Association | |
| STUDY25060149 | Other Identifier | University of Pittsburgh Institutional Review Board |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Brigham and Women's Hospital | OTHER |
| University of Pittsburgh Medical Center | OTHER |
Not provided
Not provided
Not provided
The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension in women following hypertensive disorders of pregnancy. In addition, women with overweight/obesity are at increased risk for progression to chronic hypertension after experiencing hypertensive disorders of pregnancy. Among women with hypertensive disorders of pregnancy and pre-pregnancy overweight/obesity, the investigators will conduct a randomized trial to test the effect of pharmacologically blocking the mineralocorticoid receptor for three months after delivery on blood pressure and cardiac remodeling at nine months postpartum.
The hypertensive disorders of pregnancy (HDP, e.g., gestational hypertension and preeclampsia) are a leading cause of maternal and infant morbidity and mortality and are associated with increased long-term risk of maternal atherosclerotic cardiovascular disease (CVD) and heart failure. The American College of Cardiology and American Heart Association now recognize the HDP as a sex-specific CVD risk factor to guide prescription of preventive statin therapy. Beyond this focused recommendation, however, targeted strategies for CVD risk reduction in women with HDP are not yet established. Maternal overweight/obesity is a risk factor for accelerated progression from HDP to chronic hypertension, a key mediator of heightened long-term CVD risk in women with a history of HDP, and for adverse cardiac remodeling in pregnancy. Recent preclinical evidence suggests that the HDP induce heightened vascular smooth muscle cell mineralocorticoid receptor (MR) sensitivity that persists postpartum, promoting chronic hypertension and CVD. In addition, the recent POP-HT trial suggested that blood pressure control in the very early postpartum period has long-lasting effects on the risk of chronic hypertension and cardiac remodeling in women after HDP. Integrating these lines of evidence, the investigators hypothesize that short-term pharmacologic blockade of the MR in the early postpartum period after HDP will yield long-term maternal cardiovascular benefits in women with overweight/obesity. To test this hypothesis, the investigators will compare a strategy of adding low-dose spironolactone, a breastfeeding-compatible MR antagonist, or placebo to usual care for 3 months following delivery with HDP. This multi-site trial will randomize 204 women with HDP and pre-pregnancy overweight/obesity delivering at Massachusetts General Hospital, Brigham and Women's Hospital, and the University of Pittsburgh-Magee Womens Hospital. The investigators will test the effect of short-term adjunctive postpartum spironolactone on 24-hour ambulatory blood pressure (Aim 1) and postpartum cardiac remodeling by echocardiography (Aim 2) at 9 months postpartum (i.e., 6 months after completion of study treatment).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo: Control | Placebo Comparator | Participants with Hypertensive disorders of pregnancy will receive placebo equivalent capsules to self-administer daily over the 12-week duration of the study treatment. |
|
| Treatment: Spironolactone | Experimental | Participants with hypertensive disorders of pregnancy will receive 25mg capsules of spironolactone to self-administer daily over the 12-week duration of the study treatment. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| spironolactone 25 mg orally once daily | Drug | Participants with hypertensive disorders of pregnancy will receive 25mg capsules of spironolactone to self-administer daily over the 12-week duration of the study treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| Mean 24-hour ambulatory diastolic blood pressure | 24-hour BP monitoring will be performed as part of end-of-study assessments using a validated ambulatory BP monitor. | 36 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Left ventricular relative wall thickness (main echocardiographic outcome) | Relative wall thickness is calculated as 2*posterior wall thickness/LV end-diastolic diameter as measured by transthoracic echocardiography. | Baseline and 36 weeks |
| Mean 24-hour ambulatory systolic blood pressure |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Michael C Honigberg, MD, MPP | Contact | 617-726-1843 | mhonigberg@mgh.harvard.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital | Recruiting | Boston | Massachusetts | 02114 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011225 | Pre-Eclampsia |
| D046110 | Hypertension, Pregnancy-Induced |
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D013148 | Spironolactone |
| ID | Term |
|---|---|
| D007783 | Lactones |
| D009930 | Organic Chemicals |
| D011283 | Pregnenes |
| D011278 | Pregnanes |
| D013256 |
Not provided
Not provided
Prospective, randomized, double-blind, placebo-controlled trial of low-dose spironolactone versus placebo in women with pre-pregnancy overweight/obesity who develop de novo hypertensive disorders of pregnancy
Not provided
Not provided
Not provided
| Placebo tablet to match spironolactone | Drug | Participants with Hypertensive disorders of pregnancy will receive placebo equivalent capsules to self-administer daily over the 12-week duration of the study treatment. |
|
24-hour BP monitoring will be performed as part of end-of-study assessment using a validated ambulatory BP monitor. Mean 24-hour systolic BP will be calculated from the device data. |
| 36 weeks |
| Mean diurnal ambulatory systolic blood pressure | 24-hour BP monitoring will be performed as part of the end-of-study assessment using a validated ambulatory BP monitor. Mean diurnal systolic BP will be calculated from the device data. | 36 weeks |
| Mean diurnal ambulatory diastolic blood pressure | 24-hour BP monitoring will be performed as part of the end-of-study assessment using a validated ambulatory BP monitor. Mean diurnal ambulatory diastolic blood pressure will be calculated from the device data | 36 weeks |
| Mean nocturnal ambulatory systolic blood pressure | 24-hour BP monitoring will be performed as part of the end-of-study assessment using a validated ambulatory BP monitor. Mean nocturnal ambulatory systolic blood pressure will be calculated from the device data. | 36 weeks |
| Mean nocturnal ambulatory diastolic blood pressure | 24-hour BP monitoring will be performed as part of the post-treatment assessments using a validated ambulatory BP monitor. Mean nocturnal ambulatory diastolic blood pressure will be calculated from the device data. | 36 weeks |
| Measured systolic blood pressure | At each visit, BP will be measured by study staff three times at one-minute intervals in accordance with multi-society guidelines for accurate measurement of blood pressure. The first measurement will be discarded, and the average of the second and third measurements will be recorded as the measured BP at each study visit. | Baseline, 2 weeks, 12 weeks, and 36 weeks |
| Measured diastolic blood pressure | At each visit, BP will be measured by study staff three times at one-minute intervals in accordance with multi-society guidelines for accurate measurement of blood pressure. The first measurement will be discarded, and the average of the second and third measurements will be recorded as the measured BP at each study visit. | Baseline, 2 weeks, 12 weeks, and 36 weeks |
| Readmission for hypertension | Postpartum readmission for hypertension will be captured. | Through study completion (36 weeks post-randomization) |
| All-cause readmission | All postpartum readmission will be captured | Through study completion (36 weeks post-randomization) |
| Daily defined doses of antihypertensive medication | Daily defined doses of antihypertensive medication will be quantified in accordance with the World Health Organization classification. | Baseline, 2 weeks, 12 weeks, and 36 weeks |
| Time to discontinuation of all non-study drug antihypertensive medications | All medication changes made by treating clinicians will be captured. | Through study completion (36 weeks post-randomization) |
| Escalation of antihypertensive regimen | All medication changes made by treating clinicians will be captured. | Through study completion (36 weeks post-randomization) |
| Ratio of mitral E velocity to e' [E/e'] | E/e', a measure of diastolic function, will be measured by transthoracic echocardiography. | Baseline and 36 weeks |
| Early diastolic septal mitral annular velocity [septal e'] | Septal e', a measure of diastolic function, will be measured by transthoracic echocardiography using tissue Doppler | Baseline and 36 weeks |
| Peak tricuspid regurgitant jet velocity | Peak tricuspid regurgitant jet velocity, a measure of diastolic function, will be measured by transthoracic echocardiography using continuous wave Doppler | Baseline and 36 weeks |
| Left atrial volume index | Left atrial volume index will be measured by transthoracic echocardiogarphy using the biplane method and indexed for body surface area. | Baseline and 36 weeks |
| Ratio of E to A [E/A] | E/A, a measure of diastolic function, will be measured by transthoracic echocardiography. | Baseline and 36 weeks |
| Left ventricular mass index | Left ventricular mass will be calculated from transthoracic echocardiogarphy using the Devereux formula and indexed for body surface area | Baseline and 36 weeks |
| Left ventricular ejection fraction | Left ventricular ejection fraction will be measured by transthoracic echocardiogarphy using the biplane method. | Baseline and 36 weeks |
| Left atrial reservoir strain | Left atrial strain, a sensitive measure of end- diastolic pressure and atrial remodeling, will be quantified using TOMTEC. | Baseline and 36 weeks |
| Peak global longitudinal strain | Left ventricular global longitudinal strain, a measure of subclinical cardiac dysfunction, will be quantified using TOMTEC. | Baseline and 36 weeks |
| Interventricular septal wall thickness | Interventricular septal wall thickness will be measured by transthoracic echocardiography from the parasternal long axis view. | Baseline and 36 weeks |
| Posterior wall thickness | Posterior wall thickness will be measured by transthoracic echocardiography from the parasternal long axis view. | Baseline and 36 weeks |
| High-sensitivity cardiac troponin I | High-sensitivity cardiac troponin will be measured using standard clinical assays. | Baseline, 12 weeks, and 36 weeks |
| N-terminal pro-B-type natriuretic peptide | NT-proBNP will be measured using standard clinical assays. | Baseline, 12 weeks, and 36 weeks |
| Urine microalbumin/creatinine | Urine microalbumin/creatinine will be measured using standard clinical assays. | 2 weeks, 12 weeks, and 36 weeks |
| Activin A | Activin A will be measured by ELISA. | Baseline, 2 weeks, 12 weeks, and 36 weeks |
| Soluble fms-like tyrosine kinase receptor-1 | sFlt-1 will be measured by ELISA. | Baseline, 2 weeks, 12 weeks, and 36 weeks |
| Placental growth factor | Placental growth factor will be measured by ELISA. | Baseline, 2 weeks, 12 weeks, and 36 weeks |
| Procollagen type I carboxyterminal propeptide | PICP will be measured by enzyme immunoassay. | Baseline, 12 weeks, and 36 weeks |
| Brigham and Women's Hospital | Recruiting | Boston | Massachusetts | 02115 | United States |
|
| University of Pittsburgh Magee-Womens Hospital | Not yet recruiting | Pittsburgh | Pennsylvania | 15213 | United States |
|
| D002318 | Cardiovascular Diseases |
| Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |